Keyword: Samsung BioLogics
Samsung BioLogics faces potential delisting; Merck will increase Gardasil supply to China; Chinese officials mulls new regulation for vaccine.
Korean securities watchdog has requested to review whether the company should be delisted and recommended the dismissal of its CEO.
Here is some other pharma manufacturing news of note for the week.
Former China FDA chief resigns over vaccine scandal; Astellas buys gene therapy specialist Quethera; FDA found problems at valsartan maker Huahai.
Lenvima's quarterly sales grow to $106 million; China makes 48-drug list for streamlined review; Samsung commits further investment in biologics.
Samsung BioLogics is slated to get a piece of the $22 billion investment Samsung says it will invest in growth businesses.
Eisai and Biogen's recent Alzheimer's data spark debate; Beijing works to contain a vaccine scandal; BMS and Tsinghua University pen drug discovery pact.
Korean CDMO Samsung BioLogics has won FDA approval for its first finished product at the second of three plants built in rapid succession.
Biogen and Eisai's anti-amyloid candidate shows promise; Otsuka signs two M&A deals; Samsung BioLogics faces criminal probe over Biogen JV agreement.
South Korean regulators have ruled on a case of alleged accounting violations at Samsung BioLogics and sent their findings to prosecutors.